Akums Drugs & Pharma Intrinsic Value
Akums Drugs & Pharma (AKUMS) median intrinsic value is ₹1045.16 from 10 valuation models (range ₹235–₹1959), vs current price ₹783.70 — +33.4% upside (Trading Below Calculated Value), margin of safety 25.0%. For current market price and key ratios, visit AKUMS share price screener.
AKUMS Valuation Methods Summary — DCF, Graham Number & P/E
Akums Drugs & Pharma intrinsic value across 10 models vs current price ₹783.70 — upside/downside and value range per method. Check Akums Drugs & Pharma market worth to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹486.64 | ₹389.31 - ₹583.97 | -37.9% | EPS: ₹22.12, Sector P/E: 22x |
| Book Value Method | asset | ₹1959.25 | ₹1763.33 - ₹2155.18 | +150.0% | Book Value/Share: ₹1074.52, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1567.40 | ₹1410.66 - ₹1724.14 | +100.0% | Revenue/Share: ₹1539.35, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1567.40 | ₹1410.66 - ₹1724.14 | +100.0% | EBITDA: ₹740.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1959.25 | ₹1567.40 - ₹2351.10 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹235.11 | ₹211.60 - ₹258.62 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹341.75 | ₹307.57 - ₹375.93 | -56.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1045.16 | ₹940.64 - ₹1149.68 | +33.4% | ROE: 9.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹731.29 | ₹658.16 - ₹804.42 | -6.7% | EPS: ₹22.12, BVPS: ₹1074.52 |
| Dividend Yield Method | dividend | ₹235.11 | ₹211.60 - ₹258.62 | -70.0% | DPS: ₹3.00, Target Yield: 2.5% |
AKUMS Intrinsic Value vs Market Price — All Valuation Models
Akums Drugs & Pharma fair value range ₹235–₹1959 vs current market price ₹783.70 across 10 valuation models. See AKUMS P/B ratio history to compare market price against book value per share.
AKUMS Intrinsic Value Analysis — Undervalued or Overvalued?
Akums Drugs & Pharma median intrinsic value ₹1045.16, current price ₹783.70 — Trading Below Calculated Value by 33.4%, margin of safety 25.0%.
What is the intrinsic value of AKUMS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Akums Drugs & Pharma (AKUMS) is ₹1045.16 (median value). With the current market price of ₹783.70, this represents a +33.4% variance from our estimated fair value.
The valuation range spans from ₹235.11 to ₹1959.25, indicating ₹235.11 - ₹1959.25.
Is AKUMS undervalued or overvalued?
Based on our multi-method analysis, Akums Drugs & Pharma (AKUMS) appears to be trading below calculated value by approximately 33.4%.
AKUMS Financial Health — Key Ratios vs Industry Benchmarks
Akums Drugs & Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.49 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 9.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AKUMS Cash Flow Quality — Operating & Free Cash Flow
Akums Drugs & Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,181 Cr | ₹716 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹465 Cr | ₹191 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹498 Cr | ₹333 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹177 Cr | ₹25 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹32 Cr | ₹-86 Cr | Positive Operating Cash Flow | 6/10 |